Overview

Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
Phase:
PHASE3
Details
Lead Sponsor:
Ambros Therapeutics, Inc.
Treatments:
6-amino-1-hydroxyhexane-1,1-diphosphonate